troglitazone has been researched along with Neoplasms in 5 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Santha, S | 1 |
| Davaakhuu, G | 1 |
| Basu, A | 1 |
| Ke, R | 1 |
| Das, S | 1 |
| Rana, A | 2 |
| Rana, B | 2 |
| Senthivinayagam, S | 1 |
| Mishra, P | 1 |
| Paramasivam, SK | 1 |
| Yallapragada, S | 1 |
| Chatterjee, M | 1 |
| Wong, L | 1 |
| Huang, H | 1 |
| Campbell, SC | 1 |
| Bedford, DF | 1 |
| Nelius, T | 1 |
| Veliceasa, D | 1 |
| Shroff, EH | 1 |
| Henkin, J | 1 |
| Schneider, A | 1 |
| Bouck, N | 1 |
| Volpert, OV | 1 |
| Marra, F | 1 |
| Pastacaldi, S | 1 |
2 reviews available for troglitazone and Neoplasms
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chro | 2002 |
3 other studies available for troglitazone and Neoplasms
| Article | Year |
|---|---|
Modulation of glycogen synthase kinase-3β following TRAIL combinatorial treatment in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Chromans; Drug Resistan | 2016 |
Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Caspase 3; Caspase 8; Cell | 2009 |
Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.
Topics: Angiogenesis Inhibitors; CD36 Antigens; Cells, Cultured; Chromans; Drug Interactions; Endothelium, V | 2004 |